BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Färber SF, Wurzer A, Reichart F, Beck R, Kessler H, Wester HJ, Notni J. Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6. ACS Omega 2018;3:2428-36. [PMID: 30023833 DOI: 10.1021/acsomega.8b00035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Huynh TT, Sreekumar S, Mpoy C, Rogers BE. Therapeutic Efficacy of 177Lu-Labeled A20FMDV2 Peptides Targeting ανβ6. Pharmaceuticals 2022;15:229. [DOI: 10.3390/ph15020229] [Reference Citation Analysis]
2 Urquiza M, Guevara V, Diaz-sana E, Mora F. The Role of αvβ6 Integrin Binding Molecules in the Diagnosis and Treatment of Cancer. COC 2020;24:2393-411. [DOI: 10.2174/1385272824999200528124936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Talma M, Maślanka M, Mucha A. Recent developments in the synthesis and applications of phosphinic peptide analogs. Bioorg Med Chem Lett 2019;29:1031-42. [PMID: 30846252 DOI: 10.1016/j.bmcl.2019.02.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
4 Davis RA, Hausner SH, Sutcliffe JL. Peptides as Radiopharmaceutical Vectors. In: Lewis JS, Windhorst AD, Zeglis BM, editors. Radiopharmaceutical Chemistry. Cham: Springer International Publishing; 2019. pp. 137-62. [DOI: 10.1007/978-3-319-98947-1_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Nakamoto R, Ferri V, Duan H, Hatami N, Goel M, Rosenberg J, Kimura R, Wardak M, Haywood T, Kellow R, Shen B, Park W, Iagaru A, Gambhir SS. Pilot-phase PET/CT study targeting integrin αvβ6 in pancreatic cancer patients using the cystine-knot peptide-based 18F-FP-R01-MG-F2. Eur J Nucl Med Mol Imaging 2021. [PMID: 34729628 DOI: 10.1007/s00259-021-05595-7] [Reference Citation Analysis]
6 Ludwig BS, Kessler H, Kossatz S, Reuning U. RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field. Cancers (Basel) 2021;13:1711. [PMID: 33916607 DOI: 10.3390/cancers13071711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Davis RA, Hausner SH, Harris R, Sutcliffe JL. A Comparison of Evans Blue and 4-(p-Iodophenyl)butyryl Albumin Binding Moieties on an Integrin αvβ6 Binding Peptide. Pharmaceutics 2022;14:745. [DOI: 10.3390/pharmaceutics14040745] [Reference Citation Analysis]
8 Sachindra S, Hellberg T, Exner S, Prasad S, Beindorff N, Rogalla S, Kimura R, Gambhir SS, Wiedenmann B, Grötzinger C. SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of a 177Lu-DOTA-Integrin αvβ6 Cystine Knot Peptide in a Pancreatic Cancer Xenograft Model. Front Oncol 2021;11:684713. [PMID: 34136410 DOI: 10.3389/fonc.2021.684713] [Reference Citation Analysis]
9 Quigley NG, Steiger K, Hoberück S, Czech N, Zierke MA, Kossatz S, Pretze M, Richter F, Weichert W, Pox C, Kotzerke J, Notni J. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-Trivehexin. Eur J Nucl Med Mol Imaging 2021. [PMID: 34559266 DOI: 10.1007/s00259-021-05559-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kossatz S, Beer AJ, Notni J. It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals. Cancers (Basel) 2021;13:5958. [PMID: 34885066 DOI: 10.3390/cancers13235958] [Reference Citation Analysis]
11 Shahzad K, Majid ASA, Khan M, Iqbal MA, Ali A. Recent advances in the synthesis of ( 99m Technetium) based radio-pharmaceuticals. Reviews in Inorganic Chemistry 2021;41:151-98. [DOI: 10.1515/revic-2020-0021] [Reference Citation Analysis]
12 Quigley NG, Steiger K, Richter F, Weichert W, Hoberück S, Kotzerke J, Notni J. Tracking a TGF-β activator in vivo: sensitive PET imaging of αvβ8-integrin with the Ga-68-labeled cyclic RGD octapeptide trimer Ga-68-Triveoctin. EJNMMI Res 2020;10:133. [PMID: 33128636 DOI: 10.1186/s13550-020-00706-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Hausner SH, Bold RJ, Cheuy LY, Chew HK, Daly ME, Davis RA, Foster CC, Kim EJ, Sutcliffe JL. Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma. Clin Cancer Res 2019;25:1206-15. [PMID: 30401687 DOI: 10.1158/1078-0432.CCR-18-2665] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
14 Pulido J, de Cabrera M, Sobczak AJ, Amor-Coarasa A, McGoron AJ, Wnuk SF. 4-N-Alkanoyl and 4-N-alkyl gemcitabine analogues with NOTA chelators for 68-gallium labelling. Bioorg Med Chem 2018;26:5624-30. [PMID: 30342865 DOI: 10.1016/j.bmc.2018.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Quigley NG, Czech N, Sendt W, Notni J. PET/CT imaging of pancreatic carcinoma targeting the "cancer integrin" αvβ6. Eur J Nucl Med Mol Imaging 2021. [PMID: 34109438 DOI: 10.1007/s00259-021-05443-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Wurzer A, Pollmann J, Schmidt A, Reich D, Wester HJ, Notni J. Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results. Mol Pharm 2018;15:4296-302. [PMID: 30011372 DOI: 10.1021/acs.molpharmaceut.8b00602] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
17 Quigley NG, Tomassi S, Di Leva FS, Di Maro S, Richter F, Steiger K, Kossatz S, Marinelli L, Notni J. Click-Chemistry (CuAAC) Trimerization of an αv β6 Integrin Targeting Ga-68-Peptide: Enhanced Contrast for in-Vivo PET Imaging of Human Lung Adenocarcinoma Xenografts. Chembiochem 2020;21:2836-43. [PMID: 32359011 DOI: 10.1002/cbic.202000200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]